NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Bristol-Myers Squibb
University of Maryland, Baltimore
Transgene
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
Eli Lilly and Company
Cytovation AS
Constellation Pharmaceuticals
Bristol-Myers Squibb
University of California, San Diego
BeiGene
Anaveon AG
Palleon Pharmaceuticals, Inc.
Hoffmann-La Roche
Numab Therapeutics AG
Thomas Jefferson University
Thomas Jefferson University
Intensity Therapeutics, Inc.
BeiGene
Takeda
Atara Biotherapeutics
Daiichi Sankyo
AstraZeneca
Herlev Hospital
GlaxoSmithKline
University of California, San Diego
Altor BioScience
Altor BioScience
Basilea Pharmaceutica
Altor BioScience
Servier
Theseus Pharmaceuticals
Sumitomo Pharma America, Inc.
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Advaxis, Inc.
University of Virginia
GlaxoSmithKline
Steba Biotech S.A.
Teva Branded Pharmaceutical Products R&D, Inc.
AstraZeneca
CytomX Therapeutics
Intellia Therapeutics
Apexigen America, Inc.
Processa Pharmaceuticals
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
University of Rochester